ABERNETHY MATT, Chief Financial Officer of Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in recent years, with $6.74 million in total sales compared to $2.21 million in purchases across 33 transactions. The bulk of this activity occurred in NBIX stock, with no recent buys recorded. A significant sale took place on May 15, 2024, when Abernethy disposed of shares worth $2.10 million while acquiring $1.10 million in stock via market purchases—the only notable buy in the dataset. More recently, between January and February 2026, Abernethy executed multiple sales totaling $667,517 on February 13, $171,906 on the same day, and $150,185 shortly after, alongside smaller dispositions earlier in the year. The pattern suggests consistent divestment, with the largest single sale occurring in mid-2024. While some transactions involved derivative securities or gifts (coded "G" or "A"), the majority were outright sales ("S") or market purchases ("M"). The absence of recent acquisitions and the repeated sell-side activity indicate a trend toward reducing exposure to NBIX shares over time.
AI-assisted summary